Jpmorgan Chase & CO Chemomab Therapeutics Ltd. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CMMB
# of Institutions
17Shares Held
4.55MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA1.74MShares$2.93 Million0.06% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L31.21MShares$2.04 Million0.35% of portfolio
-
Yelin Lapidot Holdings Management Ltd. Tel Aviv, L3810KShares$1.36 Million0.21% of portfolio
-
Morgan Stanley New York, NY402KShares$675,8160.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX213KShares$358,4980.06% of portfolio
About Chemomab Therapeutics Ltd.
- Ticker CMMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,431,700
- Market Cap $19.2M
- Description
- Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...